Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
NCT01214174
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
42
Enrollment
INDUSTRY
Sponsor class
Stopped
Study C11-01 started
Conditions
Ocular Inflammation
Interventions
DRUG:
IBI-10090
Sponsor
ICON Bioscience Inc